Wealthfront Advisers LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,833 shares of the medical research company's stock, valued at approximately $12,952,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Global Strategic Investment Solutions LLC bought a new stake in Thermo Fisher Scientific in the second quarter worth $612,000. Foster & Motley Inc. bought a new position in Thermo Fisher Scientific during the second quarter valued at about $2,244,000. Cypress Asset Management Inc. TX lifted its position in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Cypress Asset Management Inc. TX now owns 2,920 shares of the medical research company's stock worth $1,464,000 after buying an additional 30 shares during the last quarter. First National Bank of Omaha acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $13,895,000. Finally, Navigoe LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on TMO shares. Piper Sandler upped their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Royal Bank Of Canada lifted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday, April 24th. Finally, KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $619.41.
Get Our Latest Analysis on TMO
Thermo Fisher Scientific Stock Up 4.3%
Shares of TMO stock opened at $614.32 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a market cap of $227.14 billion, a PE ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. The stock has a 50 day moving average of $536.26 and a 200-day moving average of $508.51.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific's revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.
Insiders Place Their Bets
In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the sale, the vice president owned 14,784 shares in the company, valued at approximately $8,574,720. This represents a 28.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is currently owned by insiders.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Further Reading
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
